- Home
- ONIT vs TERN Comparison
ONIT vs TERN Comparison
Compare ONIT & TERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ONIT
- TERN
- Stock Information
- Founded
- ONIT 1988
- TERN 2017
- Country
- ONIT United States
- TERN United States
- Employees
- ONIT N/A
- TERN N/A
- Industry
- ONIT
- TERN Biotechnology: Pharmaceutical Preparations
- Sector
- ONIT
- TERN Health Care
- Exchange
- ONIT NYSE
- TERN Nasdaq
- Market Cap
- ONIT 308.3M
- TERN 324.0M
- IPO Year
- ONIT 1996
- TERN 2021
- Fundamental
- Price
- ONIT $38.00
- TERN $3.90
- Analyst Decision
- ONIT Strong Buy
- TERN Buy
- Analyst Count
- ONIT 2
- TERN 5
- Target Price
- ONIT $52.50
- TERN $15.63
- AVG Volume (30 Days)
- ONIT 39.5K
- TERN 838.1K
- Earning Date
- ONIT 07-31-2025
- TERN 08-04-2025
- Dividend Yield
- ONIT N/A
- TERN N/A
- EPS Growth
- ONIT 248.50
- TERN N/A
- EPS
- ONIT 2.98
- TERN N/A
- Revenue
- ONIT $986,700,000.00
- TERN N/A
- Revenue This Year
- ONIT $7.68
- TERN N/A
- Revenue Next Year
- ONIT $9.23
- TERN N/A
- P/E Ratio
- ONIT $12.56
- TERN N/A
- Revenue Growth
- ONIT N/A
- TERN N/A
- 52 Week Low
- ONIT $22.40
- TERN $1.87
- 52 Week High
- ONIT $41.27
- TERN $11.40
- Technical
- Relative Strength Index (RSI)
- ONIT 51.50
- TERN 62.98
- Support Level
- ONIT $36.10
- TERN $3.71
- Resistance Level
- ONIT $38.00
- TERN $4.30
- Average True Range (ATR)
- ONIT 1.25
- TERN 0.29
- MACD
- ONIT -0.20
- TERN 0.02
- Stochastic Oscillator
- ONIT 34.30
- TERN 65.49
About ONIT ONITY GROUP INC
Onity Group Inc is a non-bank mortgage servicer and originator providing solutions through its brands, PHH Mortgage and Liberty Reverse Mortgage. PHH Mortgage is one of the servicers in the country, focused on delivering a variety of servicing and lending programs. Liberty is one of the nation's reverse mortgage lenders dedicated to education and providing loans that help customers meet their personal and financial needs.
About TERN Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases. Its product candidates include TERN-701, TERN-601, TERN-501 and TERN-800.